Laquinimod fails in second RRMS study

For those of you who missed the previous comment regarding Laquinimod: Exposing the Failure of EAE

Teva Pharmaceutical Industries Ltd. (TEVA)’s experimental multiple sclerosis pill failed to reduce relapses more than placebo in a clinical trial, ….

The medicine, laquinimod, missed the key goal of the study, the Petach Tikva, Israel-based drugmaker said today in a statement. By contrast, a third group of patients who got Avonex, an older injected treatment from Biogen Idec Inc. (BIIB), had fewer relapses than those who got a placebo….

The study reported today, known as Bravo, is the second this year to show disappointing results for the medicine….

“Laquinimod is dead, if not regulatorily, then commercially,” Ori Hershkovitz, a partner at Sphera Funds Management Ltd. in Tel Aviv, said by e-mail…..”

Please see the following for the full press release: Bloomberg

CoI: Multiple

Extra reading: Laquinimod

4 thoughts on “Laquinimod fails in second RRMS study”

  1. Prof G, before I vote in your survey on "What would be your priority for MS Research money?”; I need to know what are the differences between options listed. A cure for MS will eradicate all ailments associated with the disease; therefore why give us the options to vote for lesser factors?

  2. article says 'Data from the ALLEGRO and BRAVO studies demonstrated that laquinimod reduced disability and brain tissue loss'and it quotes somebody'what I think was surprising was that the effect on disability is larger than the effect on relapses. So you have to ask yourself, what is better at the end of 2 years — to have a better physical condition or an attack less'I think relapses on their own are less of a problem than disability & progression. So why consider this a failure?

  3. Re: "So why consider this a failure?" It is only considered a failure based on the observation the trial did achieve its primary outcome, which is based on a reduction in relapses. The EMA and FDA are therefore unlikely to give it a license based on this. However, its impact on disease progression is very interesting and suggests the drug may be neuroprotective. The company is therefore planning further add-on studies to test the drug for it neuroprotective effects.

  4. Hope the research will help mankind, rather than focus on earning profits for the Company.

Leave a Reply

%d bloggers like this: